赵亮, 张晓萌, 尚涛, 王雁玲. 绝经期卵巢上皮性肿瘤患者测定血清激活素A和卵泡休止素的临床意义[J]. 中国肿瘤临床, 2004, 31(5): 281-284.
引用本文: 赵亮, 张晓萌, 尚涛, 王雁玲. 绝经期卵巢上皮性肿瘤患者测定血清激活素A和卵泡休止素的临床意义[J]. 中国肿瘤临床, 2004, 31(5): 281-284.
Zhao Liang, Zhang Xiaomeng, Shang Tao, . Study on Serum Activin A and Follistatin Levels in Postmenopausal Women with Epithelial Ovarian Carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 31(5): 281-284.
Citation: Zhao Liang, Zhang Xiaomeng, Shang Tao, . Study on Serum Activin A and Follistatin Levels in Postmenopausal Women with Epithelial Ovarian Carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 31(5): 281-284.

绝经期卵巢上皮性肿瘤患者测定血清激活素A和卵泡休止素的临床意义

Study on Serum Activin A and Follistatin Levels in Postmenopausal Women with Epithelial Ovarian Carcinoma

  • 摘要: 目的:探讨激活素A和卵泡休止素在绝经期妇女卵巢上皮性肿瘤血清浓度变化和对诊断的临床意义。方法:采用酶联免疫吸附法(ELISA)测定患者血清中激活素A和卵泡休止素的浓度,其中卵巢上皮性恶性肿瘤组48例,交界性肿瘤组12例,良性肿瘤组30例,40例正常健康的绝经期妇女作为对照组。同时测定25例卵巢上皮性恶性肿瘤患者手术前和手术后血清中激活素A和卵泡休止素的浓度变化。结果:同卵巢上皮性良性肿瘤患者和健康的对照组相比,在患卵巢上皮性恶性肿瘤患者和交界性上皮性肿瘤患者血清中激活素A的浓度明显升高(P<0.001),而卵泡休止素浓度变化无显著性意义(P=0.15)。应用对照组的第90百分位数为界值,发现有72.2%的卵巢上皮性恶性肿瘤患者血清激活素A升高,而卵泡休止素升高仅占11.2%。恶性组临床分期Ⅲ~Ⅳ期和低分化患者其血清激活素A的含量分别为1.02±0.81ng/ml和1.01±0.63mg/ml,明显高于临床分期Ⅰ~Ⅱ期患者0.79±0.55ng/ml和高~中分化患者0.86±0.65ng/ml。但血清激活素A含量与组织学类型无关(P>0.05)。卵巢上皮性恶性肿瘤组患者手术前血清激活素A浓度为1.01±0.57ng/ml,明显高于手术后0.59±0.32ng/ml(P<0.01)。结论:在绝经期卵巢上皮性恶性肿瘤患者血清中激活素A浓度明显升高,并且与肿瘤的恶性程度相关,而

     

    Abstract: Objective : To investigate the changes of serum activin A and follistatin concentrationsand the value of diagnosis in postmenopausal women with epithelial ovarian neoplasms. Methods :Serum activin A and follistatin levels in postmenopausal women with epithelial ovarian neoplasms (48cases of epithelial ovarian carcinomas, 12 cases of borderline cystadenomas, 30 cases of benign tumors)and 40 healthy postmenipausal women as controls were determined by enzyme linked immunosorbentassay (ELISA), also the change of preoperative and postoperative serum activin A and follistatin levelsof 25 cases of epithelial ovarian cancer were observed. Results : Women with epithelial ovarian cancerhad significantly higher serum levels of activin A (P<0.001),but not follistatin (P=0.15),than patients with benign tumor and normal controls. Using the 90th Gentile in the control group as the cut off ,activinA was elevated in 72.2% of women with epithelial ovarian cancer, while follistatin was elevated in11.2%. Serum activin A were significantly elevated in advanced stage (1.02+0.81ng/ml) and poorly dif-ferentiated (1.01+0.63mg/ml)compared with early staged (0.79+0.55ng/ml) and well differentiated (0.8610.65ng/ml). But there is no significant difference between activin A level and pathological types(P>0.05).The postoperative serum activin A levels (0.59+0.32ng/ml) were significantly lower than thatin preoperative(1.01+0.57ng/ml). Conclusion : These data demonstrate that activin A is more commonlyelevated than follistatin in postmenopausal women with epithelial ovarian cancer and its role as a tumormarker in the diagnosis and screening of epithelial ovarian cancer warrants further evaluation.

     

/

返回文章
返回